European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

European Pharmaceutical Review

JUNE 27, 2023

Immunotherapies can compromise the diversity and complex interactive networks in the microbial ecosystem and therefore play a role in activating or deactivating the patient’s immune response leading to variable outcomes of melanoma treatment. Trials of faecal microbiota transplantation (FMT) have demonstrated proof-of-concept in UC.

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

Pharmaceutical Technology

JUNE 16, 2025

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.

Labelling 52

Labelling Communication Hospitals Vaccines 52

PharmaShots

FEBRUARY 21, 2023

Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

PharmaShots

MAY 23, 2023

Stock Exchange: TYO With focus areas extending to the discovery and development of biopharma products, AnGes is dedicated to developing genetic medicines and therapeutic vaccines for intractable or rare diseases. Approved Cell and Gene Therapy: Collategene Founded Year: 1999 Total Employees: ~140 Headquarters: Osaka, Japan Market Cap: $162.8M

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

PharmaShots

JANUARY 31, 2023

The company’s product portfolio comprises two platforms: Virax Immune, a new-Covid-19 test detecting the T-Cell immune response to the SARS-Cov-2 virus and ViraxClear, a platform to sell a range of highly accurate diagnostic test kits and machines. Founded Year: 2014 No. Funding Value: $7.7M Founded Year: 2021 No.

Vaccines 40

Vaccines Immunization FDA 40

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunization 111